GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE236896_GSE237665_DNMT_EZH2 inhibition_1_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE236896_GSE237665_DNMT_EZH2 inhibition_1_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE236896_GSE237665_DNMT_EZH2 inhibition_1_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE236896_GSE237665_DNMT_EZH2 inhibition_1_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

ribosomal protein S4 Y-linked 1

Gene

inhibitor of DNA binding 1

Gene

DnaJ heat shock protein family (Hsp40) member A3

Gene

selenoprotein P

Gene

argininosuccinate synthase 1

Gene

adipogenesis regulatory factor

Gene

ChaC glutathione specific gamma-glutamylcyclotransferase 1

Gene

annexin A1

Gene

solute carrier family 38 member 1

Gene

tissue factor pathway inhibitor

  • Gene

    ribosomal protein S4 Y-linked 1


  • Gene

    inhibitor of DNA binding 1


  • Gene

    DnaJ heat shock protein family (Hsp40) member A3



  • Gene

    argininosuccinate synthase 1


  • Gene

    adipogenesis regulatory factor


  • Gene

    ChaC glutathione specific gamma-glutamylcyclotransferase 1



  • Gene

    solute carrier family 38 member 1


  • Gene

    tissue factor pathway inhibitor

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.